Science Sparks @ ACTREC
31 August 2026Publications
- 1. Zeineldin M, Murry JB, Shetty D, Middlezong W, Parish R, Xiao Z, Cui C, Li P, Wen J, Tang G, Zou YS (2026). Acquired ring chromosomes in hematological malignancies: A systematic evidence review for diagnostic advances, cytogenomic insights, and clinical significance by an International Consortium on Human Ring Chromosomes (ICHRC) working group. Cancer Genetics.306-307:69-90
- 2. Mohanty P, Madaan P, Patkar N, Shetty D (2026). Myeloid/lymphoid neoplasm with FLT3 rearrangement. Journal of Hematology and Allied Sciences. 6:179-81.
- 3. Krishnamurthy A, Shridhar K, Mehrotra R, Pimple S, Shashidhara LS, Dhup S, Vijayakumar M (2026). Cancer research in India: Proceedings of an expert consensus panel. Indian Journal of Cancer.
- 4. Noronha V, Menon N, Shah M, Patil V, Dhanawat A, Prakash G, Pal M, Arora A, Misra A, Goud S, More S, Yadav A, Murthy V, Maitre P, Menon S, Popat P, Sable N, Agarwal A, Rangarajan V, Shetake A, Badwe R, Prabhash K (2026). Randomized trial of adjuvant 5-FU-platinum vs paclitaxel-platinum for high-risk penile cancer. Journal of National Cancer Institute.
- 5. Mirian C, Jensen LR....Young JS, Magill ST, Bertero L... Gupta T, Patel AJ, Klisch TJ Kim JW...etal (2026). Variation in meningioma recurrence risk estimates across observational cohorts: the influence of calendar time, WHO classifications, geographical settings, and healthcare systems. Journal of Neurooncology.179(2):60.
Interesting Reads
Video of the Week
Service, Education and Research with Dr Shripad Banavali
Upcoming Events
September 3-5, 2026
At ACTREC, Tata Memorial Centre, Kharghar , Navi Mumbai
October 8-10, 2026
At ACTREC, Tata Memorial Centre, Kharghr, Navi Mumbai
October 26-29, 2026
At ACTREC, Tata Memorial Centre, Kharghar, Navi Mumbai
Do You Know?
In 2004,FDA approved bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor, for the treatment of advanced colorectal cancer. This was the first approval of an antiangiogenic agent to treat cancer
Cancer News
EurekAlert, 26/08/2026
Daraxonrasib is the first approved targeted therapy in pancreatic cancer designed to inhibit RAS, the major cancer-driving pathway in the disease. It works as a molecular glue that together with another protein, cyclophilin A, blocks the signaling of RAS proteins...
Sciencedaily, 25/08/2026
Researchers have found a way to supercharge natural killer cells, powerful immune cells that can attack cancer, so they can penetrate solid tumors and keep fighting once inside. In mice, these specially prepared tissue-resident cells slowed the growth of several tumors, including melanoma and head...
News-Medical, 25/08/2026
The researchers studied mucinous colorectal adenocarcinoma, an aggressive form of cancer that constitutes for around 10-15 percent of all colorectal cancers. It is more common in young adults and women. Unlike most colorectal cancers, mucinous colorectal adenocarcinoma spreads in the form of...
© 2026 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)